BioRad Laboratories Highlights J INTS BIO's Breakthrough NSCLC Therapy at AACR 2025
- J INTS BIO presented promising Phase 1/2 results for its EGFR-TKI therapeutic, JIN-A02, targeting NSCLC at AACR 2025.
- JIN-A02 shows efficacy in patients resistant to existing therapies, achieving significant tumor size reductions and ctDNA clearance.
- The drug demonstrates an excellent safety profile, with no serious adverse events reported in ongoing multinational trials.
Innovative Breakthrough in NSCLC Treatment: J INTS BIO Shines at AACR 2025
At the American Association for Cancer Research (AACR) 2025, J INTS BIO unveils promising advancements in cancer therapies, particularly for non-small cell lung cancer (NSCLC). The company's presentation showcases the clinical Phase 1/2 results of its next-generation EGFR-TKI therapeutic, 'JIN-A02', alongside preclinical findings for its ovarian cancer candidate, 'JIN-001'. The spotlight remains firmly on JIN-A02, which targets NSCLC, a condition that accounts for approximately 85% of all lung cancer cases and is frequently driven by mutations in the epidermal growth factor receptor (EGFR).
JIN-A02 demonstrates remarkable efficacy, particularly in patients who exhibit resistance to existing third-generation EGFR-TKIs. This is especially relevant for those with the EGFR C797S mutation, a subgroup that currently lacks approved targeted therapies. The trial results reveal a patient in the 300 mg dosage cohort achieving complete clearance of circulating tumor DNA (ctDNA) linked to the C797S or Ex19del mutations, as well as a significant reduction—over 90%—in ctDNA associated with the T790M mutation. Clinical outcomes are equally promising, with tumor size reductions reaching up to 39.7% and notable shrinkage of intracranial metastatic lesions, offering renewed hope to patients battling NSCLC, especially those with brain metastases.
Importantly, JIN-A02 presents an excellent safety profile, with no dose-limiting toxicities or serious adverse events reported even at the 300 mg dose. This aspect is particularly advantageous for patients who may require extended treatment durations or combination therapies. Currently, JIN-A02 is undergoing multinational clinical trials across Korea, the United States, and Thailand, indicating its potential for widespread application in the oncology field. The findings from J INTS BIO are set to significantly alter the treatment landscape for NSCLC patients facing resistance challenges, positioning the company at the forefront of cancer drug development.
In addition to JIN-A02, J INTS BIO's preclinical research on 'JIN-001' for ovarian cancer highlights the company's broad commitment to addressing various oncological needs. As the landscape of cancer treatment evolves, the promising results from AACR 2025 underscore the need for continuous innovation in targeted therapies, particularly for patients with limited options.